Pequliar provides computational design of patient-specific antisense oligonucleotides for rare genetic disease. It exists because the analysis that opens this door should not cost more than the families who need it can find.
Pequliar automates the bioinformatics step of ASO candidate identification — the analysis that precedes every ASO development programme. It uses thermodynamic modelling to identify optimal binding sites and scores candidates on binding affinity, off-target risk, and structural accessibility.
Synthesis-ready sequences in IDT and Eurogentec vendor notation, spanning gene-silencing, splice-switching, upregulation and experimental mechanisms, with chemistry modifications including phosphorothioate, 2′-MOE, LNA and PMO.
Pharmacologist, synthetic biologist, and pioneer of DNA origami and nucleic acid therapeutics. Postdoctoral work at MIT and in the George Church lab at Harvard Medical School. He has established five biotechnology companies that collectively secured over $300 million in funding, and serves as a visiting scientist at the Scojen Institute of Synthetic Biology at Reichman University.
His work sits at the intersection of synthetic biology, molecular design, and nucleic acid therapeutics — the exact disciplines behind individualized antisense oligonucleotides.
Pequliar is a computational research tool for informational purposes only. It automates the bioinformatics step of ASO candidate identification and makes it accessible. Pequliar is not a drug and not a drug manufacturer. It does not prescribe, recommend, or administer any compound. All sequences are computationally predicted candidates that have not been experimentally validated and require independent validation by qualified professionals.